BME:GRFBiotechs
Does Grifols (BME:GRF) Phase 3 Bet Signal a Deeper Pivot in Its Immunology Strategy?
Grifols recently reported that the first patients have been dosed in two Phase 3 trials to expand U.S. labels for its flagship immunoglobulin therapies, GAMUNEX-C and XEMBIFY, targeting secondary immunodeficiency in certain blood cancers and chronic inflammatory demyelinating polyradiculoneuropathy.
This push to broaden indications for existing plasma-derived products highlights how Grifols is trying to deepen its presence in complex, chronic immune-related conditions where immunoglobulin...